Stablepharma, a London, UK-based biotechnology firm, received a €2.5M grant through the EIC Accelerator Program.
Led by Ozgur Tuncer, CEO & Executive Director, and Dr. Steve Chatfield, Non-Executive Chairman, Stablepharma has developed StablevaX™, the technology platform that transforms approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This innovation addresses the critical global challenge of distribution, storage, and wastage issues associated with temperature-sensitive products reliant on the cold chain.
The grant comes as the company moves forward with accelerated Phase 1 clinical trials for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria vaccine in March 2025.
The trial is expected to be completed by early Q3 2025, with results anticipated by Q4 2025, and was part funded by Innovate UK.
FinSMEs
20/02/2025